About Lipopolysaccharide-binding protein
Lipopolysaccharide-binding protein (LBP) is a protein
from Homo sapiens identified by UniProt accession
P18428, 481 residues long.
MolForge cross-references it against 0 known binders and
298 disease associations.
Target properties
| Protein name | Lipopolysaccharide-binding protein |
| UniProt accession | P18428 |
| Gene | LBP |
| Organism | Homo sapiens |
| Length | 481 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (298)
Diseases linked to this target (Open Targets).
- blood protein measurement · score 0.51
- glioblastoma multiforme · score 0.23
- ovarian cancer · score 0.23
- thyroid gland adenocarcinoma · score 0.23
- head and neck squamous cell carcinoma · score 0.22
- endometrial cancer · score 0.21
- low grade glioma · score 0.18
- cutaneous melanoma · score 0.18
- lung adenocarcinoma · score 0.18
- breast adenocarcinoma · score 0.18
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P18428-F1 | alphafold | PREDICTED | 90.54 | — |
Amino-acid sequence (481 residues)
MGALARALPS ILLALLLTST PEALGANPGL VARITDKGLQ YAAQEGLLAL QSELLRITLP DFTGDLRIPH VGRGRYEFHS LNIHSCELLH SALRPVPGQG LSLSISDSSI RVQGRWKVRK SFFKLQGSFD VSVKGISISV NLLLGSESSG RPTVTASSCS SDIADVEVDM SGDLGWLLNL FHNQIESKFQ KVLESRICEM IQKSVSSDLQ PYLQTLPVTT EIDSFADIDY SLVEAPRATA QMLEVMFKGE IFHRNHRSPV TLLAAVMSLP EEHNKMVYFA ISDYVFNTAS LVYHEEGYLN FSITDDMIPP DSNIRLTTKS FRPFVPRLAR LYPNMNLELQ GSVPSAPLLN FSPGNLSVDP YMEIDAFVLL PSSSKEPVFR LSVATNVSAT LTFNTSKITG FLKPGKVKVE LKESKVGLFN AELLEALLNY YILNTFYPKF NDKLAEGFPL PLLKRVQLYD LGLQIHKDFL FLGANVQYMR V
Explore Lipopolysaccharide-binding protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets